Centanafadine - marketed as Simtriyo - becomes an FDA-approved nonstimulant ADHD medication after mixed trials, labeling concerns, and questions about real-world benefit

Centanafadine, marketed as Simtriyo, is presented as a newly approved nonstimulant medication for ADHD and is positioned within the broader search for alternatives to stimulant treatment. The subject centers on regulatory approval, clinical performance, and how a triple reuptake inhibitor might fit into ADHD care. Key details point to mixed efficacy data, safety and labeling considerations, and uncertainty about how meaningful the benefits will be outside tightly controlled trials. Nonstimulant treatment matters for people who do not tolerate stimulants, have contraindications, or need additional options, so approval expands the ADHD medication landscape even if adoption will likely depend on prescribing guidance, side-effect profile, and comparative effectiveness. ADHD treatment policy and practice are shaped not only by whether a drug is approved, but by how strongly it improves attention and functioning, how fast it works, and how clinicians weigh it against existing nonstimulants and stimulants.